Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on philadelphia Chromosome-Positive leukemia

NCT ID NCT07252336

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether specially engineered immune cells (CAR-T cells) can treat adults with a specific, aggressive form of acute lymphoblastic leukemia that has a genetic marker called the Philadelphia chromosome. Fifty newly diagnosed patients will receive an infusion of these cells. The main goal is to see if the treatment can make the cancer disappear at a molecular level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD19/CD22 CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for adults with a hard-to-treat form of leukemia, potentially improving remission rates without standard chemotherapy.
What could go wrong
This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) leukemia, acute lymphocytic, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALL

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of medical college of zhejiang university

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.